{"id":453,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"tesamorelin-hiv-lipodystrophy-randomized-trials","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/pt-br\/tesamorelin-hiv-lipodystrophy-randomized-trials\/","title":{"rendered":"Lipodistrofia associada a Tesamorelin e HIV: o que os ensaios randomizados mediram"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">Tesamorelin \u00e9 um an\u00e1logo do fator de libera\u00e7\u00e3o do horm\u00f4nio do crescimento com uma base de evid\u00eancias cl\u00ednicas definidas em adultos com lipodistrofia associada a HIV. Esse contexto espec\u00edfico da popula\u00e7\u00e3o e do par\u00e2metro de avalia\u00e7\u00e3o final \u00e9 essencial: as evid\u00eancias n\u00e3o devem ser generalizadas numa afirma\u00e7\u00e3o ampla de perda de peso por parte do consumidor.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">Principais conclus\u00f5es<\/h2><ul class=\"wp-block-list\"><li>Estudos principais mediram o tecido adiposo visceral em adultos com ac\u00famulo de gordura abdominal associado ao HIV.<\/li><li>O r\u00f3tulo FDA afirma que o produto aprovado n\u00e3o \u00e9 indicado para controle de perda de peso.<\/li><li>A evid\u00eancia de produto aprovado n\u00e3o estabelece equival\u00eancia para um material de pesquisa fornecido de forma independente.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1672\" height=\"941\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/tesamorelin-hiv-visceral-fat-research.png\" alt=\"Pesquisador revisando imagens abdominais an\u00f4nimas em um estudo de lipodistrofia associada a HIV\" class=\"wp-image-444\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/tesamorelin-hiv-visceral-fat-research.png 1672w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/tesamorelin-hiv-visceral-fat-research-300x169.png 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/tesamorelin-hiv-visceral-fat-research-1024x576.png 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/tesamorelin-hiv-visceral-fat-research-768x432.png 768w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/tesamorelin-hiv-visceral-fat-research-1536x864.png 1536w\" sizes=\"auto, (max-width: 1672px) 100vw, 1672px\" \/><figcaption class=\"wp-element-caption\">Ilustra\u00e7\u00e3o editorial original da revis\u00e3o de imagens abdominais em um estudo de lipodistrofia associada a HIV; nenhum paciente ou produto \u00e9 retratado.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">O contexto biol\u00f3gico e cl\u00ednico<\/h2><p class=\"wp-block-paragraph\">Tesamorelin \u00e9 um an\u00e1logo do fator de libera\u00e7\u00e3o do horm\u00f4nio do crescimento. No cen\u00e1rio estudado, estimula a libera\u00e7\u00e3o do horm\u00f4nio do crescimento hipofis\u00e1rio e aumenta a sinaliza\u00e7\u00e3o IGF-1. Os ensaios relevantes inclu\u00edram pessoas que viviam com HIV e que apresentavam excesso de gordura abdominal no contexto da terapia anti-retroviral.<\/p><p class=\"wp-block-paragraph\">Esse contexto \u00e9 importante porque a lipodistrofia associada \u00e0 HIV n\u00e3o \u00e9 intercambi\u00e1vel com a obesidade geral, e o tecido adiposo visceral medido por imagem n\u00e3o \u00e9 o mesmo desfecho que a perda de peso geral.<\/p><h2 class=\"wp-block-heading\">O que o estudo randomizado do m\u00eas 12 descobriu<\/h2><p class=\"wp-block-paragraph\">Um estudo randomizado controlado por placebo com participantes do 404 usou tecido adiposo visceral como desfecho prim\u00e1rio. Os investigadores relataram uma redu\u00e7\u00e3o na gordura visceral durante a fase inicial randomizada e persist\u00eancia entre os participantes que continuaram o tratamento. As melhorias foram perdidas ap\u00f3s a mudan\u00e7a da tesamorelina para o placebo, o que ajuda a esclarecer a depend\u00eancia do efeito observado na exposi\u00e7\u00e3o continuada nesse protocolo.<\/p><p class=\"wp-block-paragraph\">Um estudo randomizado menor tamb\u00e9m avaliou a gordura hep\u00e1tica e o tecido adiposo visceral. Os seus resultados foram explorat\u00f3rios para resultados relacionados com o f\u00edgado e n\u00e3o devem ser convertidos numa indica\u00e7\u00e3o aprovada de doen\u00e7a hep\u00e1tica.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Popula\u00e7\u00e3o<\/strong><span>Adultos com HIV e excesso de gordura abdominal<\/span><\/div><div class=\"pim-evidence-row\"><strong>Medi\u00e7\u00e3o prim\u00e1ria<\/strong><span>Tecido adiposo visceral por imagem<\/span><\/div><div class=\"pim-evidence-row\"><strong>Limita\u00e7\u00e3o importante<\/strong><span>N\u00e3o \u00e9 uma popula\u00e7\u00e3o ou indica\u00e7\u00e3o geral de controle de peso<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">Limites de r\u00f3tulos que pertencem a todos os resumos<\/h2><p class=\"wp-block-paragraph\">O r\u00f3tulo 2025 EGRIFTA WR identifica uma formula\u00e7\u00e3o e indica\u00e7\u00e3o espec\u00edficas aprovadas. Observa tamb\u00e9m que a seguran\u00e7a cardiovascular a longo prazo n\u00e3o foi estabelecida e que o produto n\u00e3o \u00e9 indicado para o controlo da perda de peso. Essas limita\u00e7\u00f5es fazem parte da evid\u00eancia, e n\u00e3o das letras mi\u00fadas opcionais.<\/p>","protected":false},"excerpt":{"rendered":"<p>Uma revis\u00e3o baseada em evid\u00eancias dos ensaios de tesamorelina em adultos com ac\u00famulo de gordura abdominal associado ao HIV, incluindo desfechos, limites e contexto marcado com FDA.<\/p>","protected":false},"author":1,"featured_media":623,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"367","pim_article_type":"Clinical evidence review","pim_evidence_level":"Randomized controlled human trials and FDA labeling","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Randomized tesamorelin trial with 12-month extension\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20101189\/\",\"note\":\"Primary human trial; PMID 20101189.\"},{\"title\":\"Randomized trial of visceral and liver fat outcomes\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25038357\/\",\"note\":\"Exploratory liver-fat evidence; PMID 25038357.\"},{\"title\":\"FDA EGRIFTA WR prescribing information\",\"url\":\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/022505s020lbl.pdf\",\"note\":\"Approved-product indication and limitations.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-453","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured - NHD<\/title>\n<meta name=\"description\" content=\"An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/pt-br\/tesamorelin-hiv-lipodystrophy-randomized-trials\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured\" \/>\n<meta property=\"og:description\" content=\"An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/pt-br\/tesamorelin-hiv-lipodystrophy-randomized-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\"},\"wordCount\":344,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\",\"name\":\"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/pt-br\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lipodistrofia associada a Tesamorelin e HIV: o que os ensaios randomizados mediram - NHD","description":"Uma revis\u00e3o baseada em evid\u00eancias dos ensaios de tesamorelina em adultos com ac\u00famulo de gordura abdominal associado ao HIV, incluindo desfechos, limites e contexto marcado com FDA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/pt-br\/tesamorelin-hiv-lipodystrophy-randomized-trials\/","og_locale":"pt_BR","og_type":"article","og_title":"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured","og_description":"An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.","og_url":"https:\/\/nhdbio.com\/pt-br\/tesamorelin-hiv-lipodystrophy-randomized-trials\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/"},"wordCount":344,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/","url":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/","name":"Lipodistrofia associada a Tesamorelin e HIV: o que os ensaios randomizados mediram - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Uma revis\u00e3o baseada em evid\u00eancias dos ensaios de tesamorelina em adultos com ac\u00famulo de gordura abdominal associado ao HIV, incluindo desfechos, limites e contexto marcado com FDA.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mat\u00e9rias-primas pept\u00eddicas e s\u00edntese personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipe T\u00e9cnica NHD","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"A equipe t\u00e9cnica NHD mant\u00e9m documenta\u00e7\u00e3o de cat\u00e1logo de uso em pesquisa e resumos de evid\u00eancias. Os artigos revisados \u200b\u200bvinculam-se a artigos revisados \u200b\u200bpor pares, registros de ensaios e registros regulat\u00f3rios, ret\u00eam resultados nulos e limita\u00e7\u00f5es de estudos e distinguem interven\u00e7\u00f5es publicadas de materiais de cat\u00e1logo. O desenho assistido por AI pode ser usado para estrutura; os links de origem e os limites das evid\u00eancias permanecem vis\u00edveis. Este trabalho n\u00e3o \u00e9 uma revis\u00e3o independente por pares ou aconselhamento m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/pt-br\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/comments?post=453"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/453\/revisions"}],"predecessor-version":[{"id":518,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/453\/revisions\/518"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media\/623"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media?parent=453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/categories?post=453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/tags?post=453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}